<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887484</url>
  </required_header>
  <id_info>
    <org_study_id>114544</org_study_id>
    <secondary_id>C0000-401</secondary_id>
    <nct_id>NCT00887484</nct_id>
  </id_info>
  <brief_title>A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne</brief_title>
  <official_title>A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the tolerability of topical combination therapies in
      the treatment of facial acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the tolerability of topical combination therapies in
      the treatment of facial acne.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Erythema (Redness)</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Dryness</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Peeling</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irritant/Allergic Contact Dermatitis</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema (Redness)</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Dryness</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Peeling</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritant/Allergic Contact Dermatitis</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigators Static Global Assessment</measure>
    <time_frame>Baseline, Weeks 5, 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total number of inflammatory acne lesions (pustules, papules) at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Emotional Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Functional Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Global Score</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Compliance at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?.  When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clindoxyl Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindoxyl gel</intervention_name>
    <description>Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks.  At 2 weeks, subjects will apply clindoxyl gel to the entire face for an additional 6 weeks.</description>
    <arm_group_label>Clindoxyl Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo Gel</intervention_name>
    <description>Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks.  At 2 weeks, subjects will apply clindoxyl gel to the entire face for an additional 6 weeks.</description>
    <arm_group_label>Epiduo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects at least 21 years of age, in good general health with
             documented diagnosis of acne vulgaris.

          -  Female subjects of childbearing potential must have a negative pregnancy test.
             Sexually active women of childbearing potential participating in the study must use a
             medically acceptable form of contraception  Abstinence is considered an acceptable
             method of contraception.

          -  Inflammatory (papules and pustules) and non-inflammatory (open and closed comedones)
             facial lesions.

          -  The ability and willingness to follow all study procedures, attend all scheduled
             visits, and successfully complete the study

          -  Capable of understanding and willing to provide signed and dated written voluntary
             informed consent (and any local or national authorization requirements) before any
             protocol specific procedures are performed

        Exclusion Criteria:

          -  Female subjects who are pregnant, trying to become pregnant or breastfeeding.

          -  Subjects who have any clinically relevant finding at their baseline physical other
             than acne vulgaris.

          -  History or presence of regional enteritis or inflammatory bowel disease (eg,
             ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of
             antibiotic-associated colitis) or similar symptoms.

          -  Use of topical antibiotics or anti-acne medications on the face and systemic
             antibiotics within the past 2 and 4 weeks, respectively.

          -  Use of topical corticosteroids on the face or systemic corticosteroids within the
             past 4 weeks. Use of inhaled, intra-articular or intra-lesional (other than for
             facial acne lesions) steroids is acceptable.

          -  Use of systemic retinoids within the past 6 months.

          -  Facial procedures performed by an esthetician, beautician, physician, nurse, or other
             practitioner, within the past 4 weeks or during the conduct of the study.

          -  Known hypersensitivity or previous allergic reaction to any of the active components,
             lincomycin, adapalene, clindamycin, benzoyl peroxide or excipients of the study
             product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Investigación y Prevencion de Enfermidades Cardiovasculares</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1119</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1181 ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMIPIEL - Centro Dermatológico</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1181 ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buenos Aires Skin</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1055AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>April 23, 2009</firstreceived_date>
  <firstreceived_results_date>September 22, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Acne Vulgaris</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
